STOCK TITAN

Voyager Therapeutics Inc - VYGR STOCK NEWS

Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.

Voyager Therapeutics Inc (VYGR) is a leader in developing gene therapies for central nervous system disorders through its proprietary TRACER™ platform. This page provides investors and researchers with essential updates on clinical developments, strategic partnerships, and scientific breakthroughs in AAV-based treatments.

Access curated press releases and news articles covering key milestones in Voyager’s pipeline, including therapies for Parkinson’s disease, ALS, and Friedreich’s ataxia. Stay informed about advancements in blood-brain barrier penetration technology and preclinical validation studies across multiple species.

Our repository features updates on clinical trial progress, regulatory developments, and collaborative research initiatives. Discover analysis of vector optimization achievements and manufacturing scalability efforts critical to gene therapy commercialization.

Bookmark this page for consolidated access to verified information about Voyager’s neurogenetic innovations. Check regularly for objective reporting on therapeutic candidate progression and industry leadership in CNS-targeted gene delivery solutions.

Rhea-AI Summary

Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced it will disclose its third-quarter 2022 financial and operational results before the market opens on November 8, 2022. Following the results, a live conference call and webcast will occur at 8:30 a.m. ET to discuss the findings. Interested participants can register for the call to receive dial-in details and access a live webcast on Voyager's investor website. Voyager is focused on next-generation AAV gene therapy, aiming to treat debilitating diseases using its proprietary capsids from the TRACER™ discovery platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) recently announced an employment agreement with a new hire, which includes inducement awards approved by its Compensation Committee. The agreement comprises a non-qualified stock option for 60,000 shares and restricted stock units for 30,000 shares. The stock option has a ten-year term with an exercise price of $6.01 per share and vests over four years. The restricted stock units will vest annually over three years, starting on the first anniversary of the effective date, which is set for January 1, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.8%
Tags
none
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) presented significant findings at the European Society of Gene & Cell Therapy (ESGCT) Congress 2022. The data revealed a novel cell surface receptor that enhances the delivery of Voyager's TRACER AAV capsids across the blood-brain barrier (BBB), showing potential for human translation. Additionally, preclinical results indicate ultra-low dosing might achieve therapeutic effects with reduced toxicity. These advancements could transform CNS drug delivery, underscoring Voyager's commitment to addressing critical neurological disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
none
Rhea-AI Summary

Voyager Therapeutics announced that Pfizer has exercised an option to license a novel capsid from its TRACER platform, triggering a $10 million payment. This validation could lead to further potential payments totaling up to $290 million, including development and regulatory milestones. The licensed capsid targets a rare neurologic disease and supports Voyager's strategy to enhance its internal pipeline, which includes candidates for Parkinson's and ALS. This collaboration indicates strong progress and potential in the gene therapy sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.41%
Tags
none
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) will present three posters at the 29th Annual Congress of the European Society of Gene & Cell Therapy from October 11-14, 2022, in Edinburgh, Scotland. The presentations focus on advancements in AAV gene therapy, including an engineered BBB-penetrant capsid family and evaluations of dose-response and production methodologies for AAV-based therapies. These developments may enhance treatment for neurological disorders, showcasing the company's commitment to innovation in gene therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
none
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced its participation in two upcoming investor conferences. The first is Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, featuring a company presentation at 3:45 p.m. ET. The second event is the Truist Securities Genetic Medicine Summit on October 20, 2022, where Voyager will participate in a CNS panel discussion (not webcast). Interested investors can access the presentation and archived webcasts on Voyager's website for 30 days following the events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
conferences
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced new employment agreements with Peter Pfreundschuh and another employee, granting them non-qualified stock options and restricted stock units. The stock options consist of 200,000 shares for Pfreundschuh and 76,000 shares for the other employee, both with an exercise price of $6.18 per share. These options will vest over four years, while the restricted stock units will vest annually over three years, starting from the first anniversary of the grant effective date of September 19, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.23%
Tags
none
-
Rhea-AI Summary

Voyager Therapeutics announces the appointment of new senior leaders to enhance its focus on CNS diseases. Peter Pfreundschuh joins as CFO, Todd Carter as CSO, and Trista Morrison as SVP of Corporate Affairs, effective September 19, 2022. Pfreundschuh brings over 25 years of finance experience, while Carter has significant expertise in neurology. Morrison will strengthen communications and stakeholder engagement. The company aims to maximize its AAV capsid platform and advance its pipeline addressing critical neurological conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.64%
Tags
management
-
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) has prioritized its therapeutic pipeline focusing on gene therapies for Alzheimer's, GBA1 Parkinson's, and SOD1 ALS, which have efficient paths to human proof of biology. The company reported a net loss of $19.1 million for Q2 2022, an improvement from $30.1 million in Q2 2021, aided by reduced R&D and G&A expenses. Voyager's cash position is strong, with $148.1 million as of June 30, 2022, providing a runway into 2024. Notably, Catherine J. Mackey, Ph.D., has been appointed to the Board of Directors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.23%
Tags
none
Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) recently presented data at the Alzheimer’s Association International Conference highlighting novel antibodies that inhibit the spread of pathological tau in rodent models. The research demonstrates that these antibodies, which target specific forms of tau, could advance therapeutic options for tauopathies like Alzheimer's. Notably, vectorized antibody expression showed durability exceeding six months post-administration, with substantial efficacy in reducing tau pathology in mouse models. This research builds on prior findings about the potential of their blood-brain barrier-penetrating AAV capsids.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
none
Voyager Therapeutics Inc

Nasdaq:VYGR

VYGR Rankings

VYGR Stock Data

174.45M
46.01M
17%
63.9%
4.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
LEXINGTON